EMBL: Developing a New Generation of First-in-class High Diversity Microbiome Biotherapeutics to Treat Life-threatening Diseases

By MaaT PharmaSeptember 18, 2018March 10th, 2022No Comments

Previous PostMaaT Pharma Announces First Patient Dosed in Phase 2 Clinical Trial of Lead Product MaaT013, a First-in-Class Biotherapeutic to Treat Acute GvHD
Next PostMaaT Pharma Presents Product Analysis of Its First-in-Class High Diversity Microbiome Therapeutic

We are a clinical-stage microbiome therapeutics company aiming to improve survival in cancer.

COMPANY

Home
About Us
Plateform
Pipeline
Investors
Privacy Policy

Ressources

News
Careers
Patients & HCPs

Contact

Contact Us
Twitter
LinkedIn

twitter
linkedin

Close Menu

About us
Platform
Pipeline
Patients & HCPs
News
Investors
Careers
French
Contact
Subscribe to our news

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

English
Français (French)

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

Enable or Disable Cookies

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Enable or Disable Cookies

Please enable Strictly Necessary Cookies first so that we can save your preferences!

MaaT Pharma dans les médias MaaT Pharma in the News

EMBL: Developing a New Generation of First-in-class High Diversity Microbiome Biotherapeutics to Treat Life-threatening Diseases

Previous PostMaaT Pharma Announces First Patient Dosed in Phase 2 Clinical Trial of Lead Product MaaT013, a First-in-Class Biotherapeutic to Treat Acute GvHD

Next PostMaaT Pharma Presents Product Analysis of Its First-in-Class High Diversity Microbiome Therapeutic

COMPANY

Ressources

Contact